INTRODUCTION: The Nottingham Prognostic Index (NPI) is an established prognostication tool in the management of breast cancers (BCs). Latest ten-year survival data have demonstrated an improved outlook for each NPI category and the latest UK five- and ten-year survival from BC has been reported to be 85% and 77%, respectively. We compared survival of each NPI category for BCs diagnosed within the national breast screening service in Wales (Breast Test Wales (BTW)) to the latest data, and reviewed its validity in unselected cases within a screened population. METHODS: All women screened between 1998 and 2001 within BTW were included. The NPI score for each cancer was calculated using the size, nodal status, and grade of the primary tumour. Survival data (all-cause) were calculated after ten years of follow-up. RESULTS: In the three-year screening period, 199,082 women were screened. A total of 1,712 cancers were diagnosed, and 1,546 had data available for calculating the NPI. Overall five-year and ten-year survival was 94% and 82%, respectively. CONCLUSIONS: Overall five-year and ten-year survival (all-cause) has improved even when compared with UK data for BC-specific survival. We found that the NPI remains valid for BC treatment, and that our data provide a reference for updating the all-cause survival of women diagnosed with BCs within a screened population.
INTRODUCTION: The Nottingham Prognostic Index (NPI) is an established prognostication tool in the management of breast cancers (BCs). Latest ten-year survival data have demonstrated an improved outlook for each NPI category and the latest UK five- and ten-year survival from BC has been reported to be 85% and 77%, respectively. We compared survival of each NPI category for BCs diagnosed within the national breast screening service in Wales (Breast Test Wales (BTW)) to the latest data, and reviewed its validity in unselected cases within a screened population. METHODS: All women screened between 1998 and 2001 within BTW were included. The NPI score for each cancer was calculated using the size, nodal status, and grade of the primary tumour. Survival data (all-cause) were calculated after ten years of follow-up. RESULTS: In the three-year screening period, 199,082 women were screened. A total of 1,712 cancers were diagnosed, and 1,546 had data available for calculating the NPI. Overall five-year and ten-year survival was 94% and 82%, respectively. CONCLUSIONS: Overall five-year and ten-year survival (all-cause) has improved even when compared with UK data for BC-specific survival. We found that the NPI remains valid for BC treatment, and that our data provide a reference for updating the all-cause survival of women diagnosed with BCs within a screened population.
Authors: Ivo A Olivotto; Chris D Bajdik; Peter M Ravdin; Caroline H Speers; Andrew J Coldman; Brian D Norris; Greg J Davis; Stephen K Chia; Karen A Gelmon Journal: J Clin Oncol Date: 2005-04-20 Impact factor: 44.544
Authors: László Tabár; Bedrich Vitak; Tony Hsiu-Hsi Chen; Amy Ming-Fang Yen; Anders Cohen; Tibor Tot; Sherry Yueh-Hsia Chiu; Sam Li-Sheng Chen; Jean Ching-Yuan Fann; Johan Rosell; Helena Fohlin; Robert A Smith; Stephen W Duffy Journal: Radiology Date: 2011-06-28 Impact factor: 11.105
Authors: L Tabár; C J Fagerberg; A Gad; L Baldetorp; L H Holmberg; O Gröntoft; U Ljungquist; B Lundström; J C Månson; G Eklund Journal: Lancet Date: 1985-04-13 Impact factor: 79.321
Authors: I Balslev; C K Axelsson; K Zedeler; B B Rasmussen; B Carstensen; H T Mouridsen Journal: Breast Cancer Res Treat Date: 1994 Impact factor: 4.872
Authors: M P Coleman; D Forman; H Bryant; J Butler; B Rachet; C Maringe; U Nur; E Tracey; M Coory; J Hatcher; C E McGahan; D Turner; L Marrett; M L Gjerstorff; T B Johannesen; J Adolfsson; M Lambe; G Lawrence; D Meechan; E J Morris; R Middleton; J Steward; M A Richards Journal: Lancet Date: 2010-12-21 Impact factor: 79.321
Authors: J H Todd; C Dowle; M R Williams; C W Elston; I O Ellis; C P Hinton; R W Blamey; J L Haybittle Journal: Br J Cancer Date: 1987-10 Impact factor: 7.640
Authors: J L Haybittle; R W Blamey; C W Elston; J Johnson; P J Doyle; F C Campbell; R I Nicholson; K Griffiths Journal: Br J Cancer Date: 1982-03 Impact factor: 7.640
Authors: Christopher R Manz; Ravi B Parikh; Chalanda N Evans; Corey Chivers; Susan H Regli; Justin E Bekelman; Dylan Small; Charles A L Rareshide; Nina O'Connor; Lynn M Schuchter; Lawrence N Shulman; Mitesh S Patel Journal: Contemp Clin Trials Date: 2020-01-23 Impact factor: 2.226
Authors: Aparna Gunda; Mallikarjuna S Eshwaraiah; Kiran Gangappa; Taranjot Kaur; Manjiri M Bakre Journal: Breast Cancer Res Treat Date: 2022-09-10 Impact factor: 4.624
Authors: Anita L Lynam; John M Dennis; Katharine R Owen; Richard A Oram; Angus G Jones; Beverley M Shields; Lauric A Ferrat Journal: Diagn Progn Res Date: 2020-06-04
Authors: Thuan Dang Cong; Tung Nguyen Thanh; Quynh Anh Nguyen Phan; Ai Phuong Hoang Thi; Bao Song Nguyen Tran; Quoc Huy Nguyen Vu Journal: Asian Pac J Cancer Prev Date: 2020-04-01